Denali Therapeutics Inc (DNLI)

Finanzdaten der Denali Therapeutics Inc-Aktie (DNLI)

*Alle Zahlen in Millionen

Enddatum des Zeitraums	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Periodenlänge	3 Monate	3 Monate	3 Monate	3 Monate	3 Monate
Revenues	3.60	-	-	-	-
Cost Of Revenue	0.09	-	-	-	-
	36.28	-	-	-	-
Selling, General, and Administrative	36.28	-	-	-	-
Research and Development	97.02	-	-	-	-
Costs And Expenses	134.15	-	-	-	-
Operating Income/Loss	4.96%-130.54	-137.36	-137.37	-137.43	-134.96
	0.70%-127.55	-128.45	-128.55	-126.90	-124.12
Attributable To Parent	0.70%-127.55	-128.45	-128.55	-126.90	-124.12
Basic Average Shares	0.36%187.31	186.64	0.95	172.42	171.45
Diluted Average Shares	0.36%187.31	186.64	0.95	172.42	171.45
Basic Earnings Per Share	1.45%-0.68	-0.69	-0.73	-0.74	-0.72
Diluted Earnings Per Share	1.45%-0.68	-0.69	-0.73	-0.74	-0.72